20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  International Journal of Biological Markers

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.5301/JBM.2009.1349PMID 19634108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.

  2008cited by this paper
• Comparability of tumor marker immunoassays: still an important issue for clinical diagnostics?

  2008cited by this paper
• Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards

  2008cited by this paper
• Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection.

  2008cited by this paper
• Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA.

  2007cited by this paper
• Improving the comparability of immunoassays for prostate-specific antigen (PSA): progress and problems.

  2007cited by this paper
• Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.

  2007cited by this paper
• Different prostate‐specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies

  2007cited by this paper
• Accuracy assessment of PSA methods must be based on clinical instead of artificial samples - a response to AW Roddam et al., Ann Clin Biochem 2006; 43: 35-48

  2006cited by this paper
• Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.

  2006cited by this paper
• Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation.

  2006cited by this paper
• Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England

  2006cited by this paper
• Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening.

  2004cited by this paper
• Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer?

  2001cited by this paper
• Discordant performance of assays for free and total prostate‐specific antigen in relation to the early detection of prostate cancer

  2001cited by this paper
• The clinical impact of different assays for prostate specific antigen

  2000cited by this paper
• A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA

  2000cited by this paper
• Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10)

  2000cited by this paper
• Measuring agreement in method comparison studies

  1999cited by this paper
• Comparison of 3 investigational assays for the free form of prostate specific antigen.

  1998cited by this paper
• Comparability of serum prostate-specific antigen measurement between the hybritech Tandem-R and Abbott AxSYM assays.

  1998cited by this paper
• Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen.

  1996cited by this paper
• Discordance of assay methods creates pitfalls for the interpretation of prostate‐specific antigen values

  1996cited by this paper
• Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994.

  1995cited by this paper
• Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

  1994cited by this paper

• Analytical verification and comparative assessment of the new Atellica IM high-sensitivity prostate specific antigen assay

  2025cites this paper
• Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review

  2024cites this paper
• Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays

  2024cites this paper
• Usefulness and performance evaluation of serum KL-6 and SP-A assays in healthy individuals and patients with interstitial lung disease.

  2023cites this paper
• Consistency and diagnostic accuracy of 4 assays in the detection of the total and free prostate-specific antigen

  2023cites this paper
• A New Strategy for Evaluating the Quality of Laboratory Results for Big Data Research: Using External Quality Assessment Survey Data (2010–2020)

  2023cites this paper
• Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations

  2021cites this paper
• The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers

  2021cites this paper
• Performance Evaluation of the Total ProstateSpecific Antigen (PSA), Free PSA, and [–2]proPSA Assay for Calculation of the Prostate Health Index Using the UniCel DxI 800 Analyzer

  2019cites this paper
• Focusing aptamer selection on the glycan structure of prostate-specific antigen: Toward more specific detection of prostate cancer.

  2019cites this paper
• The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients

  2017cites this paper
• Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements

  2016cites this paper
• Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)

  2014cites this paper
• Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.

  2014cites this paper
• Mechanisms of Androgen-Independent Prostate Cancer

  2014cites this paper
• Determination of Prostate-Specific Antigen in Serum and a Reference Material by On-Chip Immunoaffinity Chromatography

  2014cites this paper
• Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

  2013influential citation
• Missing agreement between the two IMMULITE® PSA assays

  2012cites this paper
• Standardization of assay methods reduces variability of total PSA measurements: an Irish study

  2012cites this paper
• Building bridges to the future of medicine: recommendations for boosting development of novel and companion diagnostics.

  2012cites this paper
• Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

  2011cites this paper
• GLYCANS AS BIOMARKERS: STATUS AND PERSPECTIVES GLIKANI KAO BIOMARKERI: STATUS I PERSPEKTIVE

  2011cites this paper
• Glycans as Biomarkers: Status and Perspectives

  2011cites this paper
• CLSI EP17-A protocol: a useful tool for better understanding the low end performance of total prostate-specific antigen assays.

  2011cites this paper
• An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

  2011cites this paper
• Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

  2011cites this paper
• Tumor markers in prostate cancer I: Blood-based markers

  2011cites this paper
• On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.

  2010cites this paper
• Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access® prostate-specific antigen assays

  2010cites this paper